Annual Report 2019

Department of Hematopoietic Stem Cell Transplantation

Takahiro Fukuda, Sung-Won Kim, Yoshihiro Inamoto, Takashi Tanaka, Ayumu Ito, Jun Aoki, Minoru Kojima, Tsuneaki Hirakawa, Wataru Takeda

Introduction

 We specialize in patients who undergo allogeneic or autologous hematopoietic stem cell transplantation (HSCT). Our transplant units include 26 beds in ward 12B and 3 beds in ward 11A. All rooms are filtered by a central high-efficiency particulate air filtration system.

The Team and What We Do

 Seven staff physicians (Drs. Kim, Inamoto, Tanaka, Ito, Aoki, Kojima and Fukuda) and 2 chief residents (Drs. Hirakawa and Takeda) participate in the transplant program. Pediatric patients who undergo HSCT are managed in collaboration with Dr. Ogawa, the chief of the Pediatric Oncology Division, and other pediatricians. In fiscal 2019, a total of 93 HSCTs were performed. The numbers of each type of HCST in fiscal 2019 are shown in Table 1, and the numbers of patients according to disease type are shown in Table 2.

 We discuss approximately 30 HSCT inpatients and those who consulted us for indication of HSCT every week at the collaborative conference on Monday with the Departments of Hematology and Pediatric Oncology. The transplant unit is staffed by 25 nurses trained in oncology and specialized supportive care for HSCT patients. The nursing unit has been assuming leadership roles in an effort to facilitate improved care for graft-versus-host disease (GVHD), and establishment of a Long-term Follow-up Unit (LTFU) for the education of patients and their family members. In fiscal 2019, we saw 382 patients at the LTFU clinic. We discuss all HSCT inpatients in detail among all transplant team members including physicians, nurses, pharmacists, the nutritional support team, the rehabilitation team, mental support team, and the hematopoietic cell transplant coordinator (HCTC) every week on Friday.

Table 1. Number of each type of HSCT

Table 2. Number of patients who underwent HSCT in fiscal 2019

Research activities / Clinical trials

 We completed a phase I/II multicenter trial to determine the safety and efficacy of peripheral blood stem cell transplantation (PBSCT) from an HLA-haploidentical donor with PTCY in patients with aggressive adult T-cell leukemia/lymphoma (ATL) (UMIN000021783). We concluded that PBSCT from an HLA-haploidentical donor with PTCY is feasible and promising for patients with aggressive ATL (Tanaka, JSH 2019). We also completed a prospective, observational study to clarify the treatment outcomes of aggressive ATL, which suggest that more frequent application of allo-HSCT improved the survival of patients with aggressive ATL (Ito, JSH 2019). We have published an international collaborative study that compared characteristics and outcomes of late acute and NIH chronic GVHD between Japanese and white patients (Inamoto, Blood Adv 2019). We have published two nationwide studies that showed the association of post-transplant quality of life with the activity of chronic GVHD (Kurosawa, BBMT 2019) or employment status (Kurosawa, BMT 2019). In fiscal 2019, we published 71 articles in peer-reviewed international journals.

Education

 We trained 6 residents to develop their clinical skills for management of HSCT patients in fiscal 2019. We also conducted education on how to perform clinical studies. Since 2018, our residents have published 11 articles as a first author.

Future prospects

 Our goal is to develop optimal strategies of HSCT to cure hematologic malignancies for as many patients as possible.

List of papers published in 2019

Journal

1. Inamoto Y, White J, Ito R, Martin PJ, Fatobene G, Ito A, Tanaka T, Kurosawa S, Kim SW, Bar M, Sorror ML, Sandmaier BM, Lee SJ, Fukuda T, Flowers MED. Comparison of characteristics and outcomes of late acute and NIH chronic GVHD between Japanese and white patients. Blood Adv, 3:2764-2777, 2019

2. Kurosawa S, Yamaguchi T, Oshima K, Yanagisawa A, Fukuda T, Kanamori H, Mori T, Takahashi S, Kondo T, Kohno A, Miyamura K, Umemoto Y, Teshima T, Taniguchi S, Yamashita T, Inamoto Y, Kanda Y, Okamoto S, Atsuta Y. Resolved versus Active Chronic Graft-versus-Host Disease: Impact on Post-Transplantation Quality of Life. Biol Blood Marrow Transplant, 25:1851-1858, 2019

3. Kurosawa S, Yamaguchi T, Oshima K, Yanagisawa A, Fukuda T, Kanamori H, Mori T, Takahashi S, Kondo T, Fujisawa S, Onishi Y, Yano S, Onizuka M, Kanda Y, Mizuno I, Taniguchi S, Yamashita T, Inamoto Y, Okamoto S, Atsuta Y. Employment status was highly associated with quality of life after allogeneic hematopoietic cell transplantation, and the association may differ according to patient age and graft-versus-host disease status: analysis of a nationwide QOL survey. Bone Marrow Transplant, 54:611-615, 2019

4. Kanda Y, Kimura SI, Iino M, Fukuda T, Sakaida E, Oyake T, Yamaguchi H, Fujiwara SI, Jo Y, Okamoto A, Fujita H, Takamatsu Y, Saburi Y, Matsumura I, Yamanouchi J, Shiratori S, Gotoh M, Nakamura S, Tamura K. D-Index-Guided Early Antifungal Therapy Versus Empiric Antifungal Therapy for Persistent Febrile Neutropenia: A Randomized Controlled Noninferiority Trial. J Clin Oncol, 38:815-822, 2020

5. Sakatoku K, Ito A, Tajima K, Yamaguchi K, Kuno M, Aoki N, Tanaka T, Kurosawa S, Inamoto Y, Kim SW, Fukuda T. Prognostic significance of low pre-transplant skeletal muscle mass on survival outcomes in patients undergoing hematopoietic stem cell transplantation. Int J Hematol, 111:267-277, 2020

6. Kawajiri A, Kitano S, Maeshima AM, Inamoto Y, Tajima K, Takemura T, Tanaka T, Ito A, Okinaka K, Kurosawa S, Kim SW, Taniguchi H, Ogawa C, Izutsu K, Yamamoto N, Fukuda T. Association of CD204+ macrophages with poor outcomes of malignant lymphomas not in remission treated by allogeneic HCT. Eur J Haematol, 103:578-587, 2019

7. Yuda S, Fuji S, Onishi A, Tanaka T, Inamoto Y, Kurosawa S, Kim SW, Fukuda T. Extramedullary Relapse of Acute Myelogenous Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant, 25:1152-1157, 2019

8. Ito A, Kitano S, Tajima K, Kim Y, Tanaka T, Inamoto Y, Kim SW, Yamamoto N, Fukuda T, Okamoto S. Impact of low-dose anti-thymocyte globulin on immune reconstitution after allogeneic hematopoietic cell transplantation. Int J Hematol, 111:120-130, 2020

9. Fuji S, Kurosawa S, Inamoto Y, Murata T, Utsunomiya A, Uchimaru K, Yamasaki S, Inoue Y, Moriuchi Y, Choi I, Ogata M, Hidaka M, Yamaguchi T, Fukuda T. A decision analysis comparing unrelated bone marrow transplantation and cord blood transplantation in patients with aggressive adult T-cell leukemia-lymphoma. Int J Hematol, 111:427-433, 2020

10.Fuji S, Yamaguchi T, Inoue Y, Utsunomiya A, Moriuchi Y, Owatari S, Miyagi T, Sawayama Y, Otsuka E, Yoshida SI, Fukuda T. VCAP-AMP-VECP as a preferable induction chemotherapy in transplant-eligible patients with aggressive adult T-cell leukemia-lymphoma: a propensity score analysis. Bone Marrow Transplant, 54:1399-1405, 2019

11. Inamoto Y, Lee SJ, Onstad LE, Flowers MED, Hamilton BK, Jagasia MH, Martin PJ, Pavletic SZ, Pidala JA, Pusic I, Vogelsang GB, Wolff D, Carpenter PA. Refined National Institutes of Health response algorithm for chronic graft-versus-host disease in joints and fascia. Blood Adv, 4:40-46, 2020

12. Inamoto Y, Valdés-Sanz N, Ogawa Y, Alves M, Berchicci L, Galvin J, Greinix H, Hale GA, Horn B, Kelly D, Liu H, Rowley S, Schoemans H, Shah A, Lupo Stanghellini MT, Agrawal V, Ahmed I, Ali A, Bhatt N, Byrne M, Chhabra S, DeFilipp Z, Fahnehjelm K, Farhadfar N, Horn E, Lee C, Nathan S, Penack O, Prasad P, Rotz S, Rovó A, Yared J, Pavletic S, Basak GW, Battiwalla M, Duarte R, Savani BN, Flowers MED, Shaw BE, Petriček I. Ocular graft-versus-host disease after hematopoietic cell transplantation: Expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT. Bone Marrow Transplant, 54:662-673, 2019

13. Inamoto Y, Petriček I, Burns L, Chhabra S, DeFilipp Z, Hematti P, Rovó A, Schears R, Shah A, Agrawal V, Ahmed A, Ahmed I, Ali A, Aljurf M, Alkhateeb H, Beitinjaneh A, Bhatt N, Buchbinder D, Byrne M, Callander N, Fahnehjelm K, Farhadfar N, Gale RP, Ganguly S, Hashmi S, Hildebrandt GC, Horn E, Jakubowski A, Kamble RT, Law J, Lee C, Nathan S, Penack O, Pingali R, Prasad P, Pulanic D, Rotz S, Shreenivas A, Steinberg A, Tabbara K, Tichelli A, Wirk B, Yared J, Basak GW, Battiwalla M, Duarte R, Savani BN, Flowers MED, Shaw BE, Valdés-Sanz N. Non-Graft-versus-Host Disease Ocular Complications after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and the Transplant Complications Working Party of the European Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant, 25:e145-e154, 2019

14. Inamoto Y. Alternative donors: a match for matched sibling donors? Lancet Haematol, 6:e545-e546, 2019

15. Nakashima T, Tanaka T, Koido K, Nishibuchi Y, Hashimoto H, Ito A, Inamoto Y, Kurosawa S, Kim SW, Fukuda T, Terakado H. Comparison of valproate and levetiracetam for the prevention of busulfan-induced seizures in hematopoietic stem cell transplantation. Int J Hematol, 109:694-699, 2019

16. Inoki K, Kakugawa Y, Takamaru H, Sekiguchi M, Matsumoto M, Matsuda T, Ito A, Tanaka T, Inamoto Y, Fuji S, Kurosawa S, Kim SW, Fukuda T, Ohe Y, Saito Y. Capsule Endoscopy after Hematopoietic Stem Cell Transplantation Can Predict Transplant-Related Mortality. Digestion, 101:198-207, 2020

17. Kato F, Daiko H, Kanamori J, Inamoto Y, Fukuda T, Hayashi K, Tachimori Y, Koyanagi K. Esophagectomy for the patients with squamous cell carcinoma of the esophagus after allogeneic hematopoietic stem cell transplantation. Int J Clin Oncol, 25:82-88, 2020

18. Sudo K, Kato K, Matsuzaki J, Boku N, Abe S, Saito Y, Daiko H, Takizawa S, Aoki Y, Sakamoto H, Niida S, Takeshita F, Fukuda T, Ochiya T. Development and Validation of an Esophageal Squamous Cell Carcinoma Detection Model by Large-Scale MicroRNA Profiling. JAMA Netw Open, 2:e194573, 2019

19. Yakushijin K, Ikezoe T, Ohwada C, Kudo K, Okamura H, Goto H, Yabe H, Yasumoto A, Kuwabara H, Fujii S, Kagawa K, Ogata M, Onishi Y, Kohno A, Watamoto K, Uoshima N, Nakamura D, Ota S, Ueda Y, Oyake T, Koike K, Mizuno I, Iida H, Katayama Y, Ago H, Kato K, Okamura A, Kikuta A, Fukuda T. Clinical effects of recombinant thrombomodulin and defibrotide on sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant, 54:674-680, 2019

20. Sakaguchi M, Yamaguchi H, Kuboyama M, Najima Y, Usuki K, Ueki T, Oh I, Mori S, Kawata E, Uoshima N, Kobayashi Y, Kako S, Tajika K, Shono K, Kayamori K, Hagihara M, Kanda J, Uchiyama H, Kuroda J, Uchida N, Kubota Y, Kimura S, Kurosawa S, Date K, Nakajima N, Marumo A, Omori I, Fujiwara Y, Terada K, Yui S, Wakita S, Arai K, Kitano T, Kakihana K, Kanda Y, Ohashi K, Fukuda T, Inokuchi K. Significance of FLT3-tyrosine kinase domain mutation as a prognostic factor for acute myeloid leukemia. Int J Hematol, 110:566-574, 2019

21. Takano K, Ogata M, Satou T, Miyazaki Y, Otsuka E, Saito N, Ueki T, Kako S, Fukuda T, Shirao K. Correlations of cytokine levels in cerebrospinal fluid and peripheral blood with outcome of HHV-6B encephalitis after hematopoietic stem cell transplantation. Transpl Infect Dis, 21:e13172, 2019

22. Kawashima N, Iida M, Suzuki R, Fukuda T, Atsuta Y, Hashii Y, Inoue M, Kobayashi M, Yabe H, Okada K, Adachi S, Yuza Y, Kawa K, Kato K. Prophylaxis and treatment with mycophenolate mofetil in children with graft-versus-host disease undergoing allogeneic hematopoietic stem cell transplantation: a nationwide survey in Japan. Int J Hematol, 109:491-498, 2019

23. Mohty M, Malard F, Abecasis M, Aerts E, Alaskar AS, Aljurf M, Arat M, Bader P, Baron F, Basak G, Bazarbachi A, Blaise D, Ciceri F, Corbacioglu S, Dalle JH, Dignan F, Fukuda T, Huynh A, Kuball J, Lachance S, Lazarus H, Masszi T, Michallet M, Nagler A, NiChonghaile M, Okamoto S, Pagliuca A, Peters C, Petersen FB, Richardson PG, Ruutu T, Saber W, Savani BN, Soiffer R, Styczynski J, Wallhult E, Yakoub-Agha I, Duarte RF, Carreras E. Prophylactic, preemptive, and curative treatment for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a position statement from an international expert group. Bone Marrow Transplant, 55:485-495, 2020

24. Lee CJ, Kim S, Tecca HR, Bo-Subait S, Phelan R, Brazauskas R, Buchbinder D, Hamilton BK, Battiwalla M, Majhail NS, Lazarus HM, Shaw PJ, Marks DI, Litzow MR, Chhabra S, Inamoto Y, DeFilipp Z, Hildebrandt GC, Olsson RF, Kasow KA, Liesveld JL, Rotz SJ, Badawy SM, Bhatt NS, Yared JA, Page KM, Arellano ML, Kent M, Farhadfar N, Seo S, Hematti P, Freytes CO, Rovó A, Ganguly S, Nathan S, Burns L, Shaw BE, Muffly LS. Late effects after ablative allogeneic stem cell transplantation for adolescent and young adult acute myeloid leukemia. Blood Adv, 4:983-992, 2020

25. Buchbinder D, Brazauskas R, Bo-Subait K, Ballen K, Parsons S, John T, Hahn T, Sharma A, Steinberg A, D'Souza A, Kumar AJ, Yoshimi A, Wirk B, Shaw B, Freytes C, LeMaistre C, Bredeson C, Dandoy C, Almaguer D, Marks DI, Szwajcer D, Hale G, Schouten H, Hashem H, Schoemans H, Murthy HS, Lazarus HM, Cerny J, Tay J, Yared JA, Adekola K, Schultz KR, Lehmann L, Burns L, Aljurf M, Diaz MA, Majhail N, Farhadfar N, Kamble R, Olsson R, Schears R, Seo S, Beattie S, Chhabra S, Savani BN, Badawy S, Ganguly S, Ciurea S, Marino S, Gergis U, Kuwatsuka Y, Inamoto Y, Khera N, Hashmi S, Wood W, Saber W. Predictors of Loss to Follow-Up Among Pediatric and Adult Hematopoietic Cell Transplantation Survivors: A Report from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant, 26:553-561, 2020

26. DeFilipp Z, Ancheta R, Liu Y, Hu ZH, Gale RP, Snyder D, Schouten HC, Kalaycio M, Hildebrandt GC, Ustun C, Daly A, Ganguly S, Inamoto Y, Litzow M, Szer J, Savoie ML, Hossain N, Kharfan-Dabaja MA, Hamadani M, Reshef R, Bajel A, Schultz KR, Gadalla S, Gerds A, Liesveld J, Juckett MB, Kamble R, Hashmi S, Abdel-Azim H, Solh M, Bacher U, Lazarus H, Olsson R, Cahn JY, Grunwald MR, Savani BN, Yared J, Rowe JM, Cerny J, Chaudhri NA, Aljurf M, Beitinjaneh A, Seo S, Nishihori T, Hsu JW, Ramanathan M, Alyea E, Popat U, Sobecks R, Saber W. Maintenance Tyrosine Kinase Inhibitors Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia: A Center for International Blood and Marrow Transplant Research Study. Biol Blood Marrow Transplant, 26:472-479, 2020

27. DeFilipp Z, Advani AS, Bachanova V, Cassaday RD, Deangelo DJ, Kebriaei P, Rowe JM, Seftel MD, Stock W, Tallman MS, Fanning S, Inamoto Y, Kansagra A, Johnston L, Nagler A, Sauter CS, Savani BN, Perales MA, Carpenter PA, Larson RA, Weisdorf D. Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy. Biol Blood Marrow Transplant, 25:2113-2123, 2019

28. Kim HT, Ahn KW, Hu ZH, Davids MS, Volpe VO, Antin JH, Sorror ML, Shadman M, Press O, Pidala J, Hogan W, Negrin R, Devine S, Uberti J, Agura E, Nash R, Mehta J, McGuirk J, Forman S, Langston A, Giralt SA, Perales MA, Battiwalla M, Hale GA, Gale RP, Marks DI, Hamadani M, Ganguly S, Bacher U, Lazarus H, Reshef R, Hildebrandt GC, Inamoto Y, Cahn JY, Solh M, Kharfan-Dabaja MA, Ghosh N, Saad A, Aljurf M, Schouten HC, Hill BT, Pawarode A, Kindwall-Keller T, Saba N, Copelan EA, Nathan S, Beitinjaneh A, Savani BN, Cerny J, Grunwald MR, Yared J, Wirk BM, Nishihori T, Chhabra S, Olsson RF, Bashey A, Gergis U, Popat U, Sobecks R, Alyea E, Saber W, Brown JR. Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report. Clin Cancer Res, 25:5143-5155, 2019

29. Hamilton BK, Liu Y, Hemmer MT, Majhail N, Ringden O, Kim D, Costa L, Stuart R, Alousi A, Pidala JA, Couriel DR, Aljurf M, Antin JH, Bredeson C, Cahn JY, Cairo M, Choi SW, Dandoy C, Gale RP, Gergis U, Hematti P, Inamoto Y, Kamble RT, MacMillan M, Marks DI, Nemecek E, Nishihori T, Saad A, Savani BN, Schriber J, Seo S, Socié G, Teshima T, Verdonck LF, Waller EK, Wirk M, Spellman SR, Arora M, Chhabra S. Inferior Outcomes with Cyclosporine and Mycophenolate Mofetil after Myeloablative Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant, 25:1744-1755, 2019

30. Mehta RS, Holtan SG, Wang T, Hemmer MT, Spellman SR, Arora M, Couriel DR, Alousi AM, Pidala J, Abdel-Azim H, Ahmed I, Aljurf M, Askar M, Auletta JJ, Bhatt V, Bredeson C, Chhabra S, Gadalla S, Gajewski J, Gale RP, Gergis U, Hematti P, Hildebrandt GC, Inamoto Y, Kitko C, Khandelwal P, MacMillan ML, Majhail N, Marks DI, Mehta P, Nishihori T, Olsson RF, Pawarode A, Diaz MA, Prestidge T, Qayed M, Rangarajan H, Ringden O, Saad A, Savani BN, Seo S, Shah A, Shah N, Schultz KR, Solh M, Spitzer T, Szer J, Teshima T, Verdonck LF, Williams KM, Wirk B, Wagner J, Yared JA, Weisdorf DJ. GRFS and CRFS in alternative donor hematopoietic cell transplantation for pediatric patients with acute leukemia. Blood Adv, 3:1441-1449, 2019

31. Kaito S, Nakajima Y, Hara K, Toya T, Nishida T, Uchida N, Mukae J, Fukuda T, Ozawa Y, Tanaka M, Ikegame K, Katayama Y, Kuriyama T, Kanda J, Atsuta Y, Ogata M, Taguchi A, Ohashi K. Heterogeneous impact of cytomegalovirus reactivation on nonrelapse mortality in hematopoietic stem cell transplantation. Blood Adv, 4:1051-1061, 2020 

32. Horio T, Morishita E, Mizuno S, Uchino K, Hanamura I, Espinoza JL, Morishima Y, Kodera Y, Onizuka M, Kashiwase K, Fukuda T, Doki N, Miyamura K, Mori T, Nakao S, Takami A. Donor Heme Oxygenase-1 Promoter Gene Polymorphism Predicts Survival after Unrelated Bone Marrow Transplantation for High-Risk Patients. Cancers (Basel), 12:424, 2020 

33. Arima N, Kanda J, Yabe T, Morishima Y, Tanaka J, Kako S, Sakaguchi H, Kato M, Ohashi K, Ozawa Y, Fukuda T, Ota S, Tachibana T, Onizuka M, Ichinohe T, Atsuta Y, Kanda Y. Increased Relapse Risk of Acute Lymphoid Leukemia in Homozygous HLA-C1 Patients after HLA-Matched Allogeneic Transplantation: A Japanese National Registry Study. Biol Blood Marrow Transplant, 26:431-437, 2020 

34. Kako S, Yamazaki H, Ohashi K, Ozawa Y, Ota S, Kanda Y, Maeda T, Kato J, Ishiyama K, Matsuoka KI, Miyamoto T, Iida H, Ikegame K, Fukuda T, Ichinohe T, Atsuta Y, Mori T. Mixed Chimerism and Secondary Graft Failure in Allogeneic Hematopoietic Stem Cell Transplantation for Aplastic Anemia. Biol Blood Marrow Transplant, 26:445-450, 2020 

35. Yanada M, Takami A, Mizuno S, Mori J, Chou T, Usuki K, Uchiyama H, Amano I, Fujii S, Miyamoto T, Saito T, Kamimura T, Ichinohe T, Fukuda T, Okamoto S, Atsuta Y, Yano S. Autologous hematopoietic cell transplantation for acute myeloid leukemia in adults: 25 years of experience in Japan. Int J Hematol, 111:93-102, 2020 

36. Yanada M, Konuma T, Yamasaki S, Kuwatsuka Y, Masuko M, Tanaka M, Ozawa Y, Toya T, Fukuda T, Ota S, Sawa M, Uchida N, Nakamae H, Eto T, Kanda J, Takanashi M, Kanda Y, Atsuta Y, Yano S. Time-Varying Effects of Graft Type on Outcomes for Patients with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant, 26:307-315, 2020 

37. Konuma T, Kondo T, Mizuno S, Doki N, Aoki J, Fukuda T, Tanaka M, Sawa M, Katayama Y, Uchida N, Ozawa Y, Morishige S, Matsuoka KI, Ichinohe T, Onizuka M, Kanda J, Atsuta Y, Yanada M. Conditioning Intensity for Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients with Poor-Prognosis Cytogenetics in First Complete Remission. Biol Blood Marrow Transplant, 26:463-471, 2020 

38. Morishima Y, Morishima S, Murata M, Arima N, Uchida N, Sugio Y, Takahashi S, Matsuhashi Y, Onizuka M, Eto T, Nagafuji K, Onishi Y, Inoue M, Atsuta Y, Fukuda T, Ichinohe T, Kato S, Kanda J. Impact of Homozygous Conserved Extended HLA Haplotype on Single Cord Blood Transplantation: Lessons for Induced Pluripotent Stem Cell Banking and Transplantation in Allogeneic Settings. Biol Blood Marrow Transplant, 26:132-138, 2020 

39. Shinohara A, Oshima K, Fuji S, Umeda K, Kako S, Kurokawa M, Tsukada N, Kasai M, Kondo T, Hashii Y, Nakamae H, Ikegame K, Kosaka Y, Shimada A, Nawa Y, Makoto Y, Yoshiko A, Fukuda T, Tanaka J, Ogata M. Hematopoietic Stem Cell Transplantation in Solid Organ Recipients with Emphasis on Transplant Complications: A Nationwide Retrospective Survey on Behalf of the Japan Society for Hematopoietic Stem Cell Transplantation Transplant Complications Working Group. Biol Blood Marrow Transplant, 26:66-75, 2020

40. Kanda J, Hayashi H, Ruggeri A, Kimura F, Volt F, Takahashi S, Labopin M, Kako S, Tozatto-Maio K, Yano S, Sanz G, Uchida N, Van Lint MT, Kato S, Mohty M, Forcade E, Kanamori H, Sierra J, Ohno Y, Saccardi R, Fukuda T, Ichinohe T, Takanashi M, Rocha V, Okamoto S, Nagler A, Atsuta Y, Gluckman E. Prognostic factors for adult single cord blood transplantation among European and Japanese populations: the Eurocord/ALWP-EBMT and JSHCT/JDCHCT collaborative study. Leukemia, 34:128-137, 2020

41. Nishiwaki S, Miyamura K, Kanda Y, Takanashi M, Uchida N, Fukuda T, Ikegame K, Ohashi K, Eto T, Ozawa Y, Shiratori S, Iwato K, Matsuoka KI, Hidaka M, Ichinohe T, Atsuta Y, Kodera Y, Okamoto S. A consideration for efficient unrelated hematopoietic stem cell source acquisition-from an experience of Japan. Bone Marrow Transplant, 55:657-660, 2020

42. Yamasaki S, Aoki J, Mori J, Mizuno S, Uchida N, Ohashi K, Fukuda T, Ikegame K, Eto T, Ogawa Y, Tanaka M, Hidaka M, Iwato K, Sawa M, Ichinohe T, Kanda Y, Atsuta Y, Yanada M, Yano S. Better disease control before allogeneic stem cell transplantation is crucial to improve the outcomes of transplantation for acute myeloid leukemia patients with extramedullary disease. Bone Marrow Transplant, 55:249-252, 2020

43. Nakasone H, Kawamura K, Yakushijin K, Shinohara A, Tanaka M, Ohashi K, Ota S, Uchida N, Fukuda T, Nakamae H, Matsuoka KI, Kanda J, Ichinohe T, Atsuta Y, Inamoto Y, Seo S, Kimura F, Ogata M. BM is preferred over PBSCs in transplantation from an HLA-matched related female donor to a male recipient. Blood Adv, 3:1750-1760, 2019

44. Arai Y, Kondo T, Fuse K, Shibasaki Y, Masuko M, Sugita J, Teshima T, Uchida N, Fukuda T, Kakihana K, Ozawa Y, Eto T, Tanaka M, Ikegame K, Mori T, Iwato K, Ichinohe T, Kanda Y, Atsuta Y. Using a machine learning algorithm to predict acute graft-versus-host disease following allogeneic transplantation. Blood Adv, 3:3626-3634, 2019

45. Fukano R, Mori T, Fujita N, Kobayashi R, Mitsui T, Kato K, Suzuki R, Suzumiya J, Fukuda T, Shindo M, Maseki N, Shimoyama T, Okada K, Inoue M, Inagaki J, Hashii Y, Sato A, Tabuchi K. Successful outcome with reduced-intensity condition regimen followed by allogeneic hematopoietic stem cell transplantation for relapsed or refractory anaplastic large-cell lymphoma. Int J Hematol, 110:723-728, 2019

46. Nishiwaki S, Mizuta S, Ohashi K, Fukuda T, Uchida N, Tachibana T, Onizuka M, Ozawa Y, Onishi Y, Takahashi S, Eto T, Nakamae H, Tanaka J, Ichinohe T, Atsuta Y, Kako S. Different impact of BCR-ABL transcripts on allogeneic hematopoietic cell transplantation from different graft sources for Ph + ALL with minimal residual disease. Am J Hematol, 94:E301-E305, 2019

47. Akahoshi Y, Nishiwaki S, Mizuta S, Ohashi K, Uchida N, Tanaka M, Fukuda T, Ozawa Y, Takahashi S, Onizuka M, Shiratori S, Nakamae H, Kanda Y, Ichinohe T, Atsuta Y, Kako S. Tyrosine kinase inhibitor prophylaxis after transplant for Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer Sci, 110:3255-3266, 2019

48. Kawase T, Tanaka H, Kojima H, Uchida N, Ohashi K, Fukuda T, Ozawa Y, Ikegame K, Eto T, Mori T, Miyamoto T, Hidaka M, Shiratori S, Takanashi M, Atsuta Y, Ichinohe T, Kanda Y, Kanda J. Impact of High-Frequency HLA Haplotypes on Clinical Cytomegalovirus Reactivation in Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant, 25:2482-2489, 2019

49. Kondo E, Shimizu-Koresawa R, Chihara D, Mizuta S, Izutsu K, Ikegame K, Uchida N, Fukuda T, Ichinohe T, Atsuta Y, Suzuki R. Allogeneic haematopoietic stem cell transplantation for primary mediastinal large B-cell lymphoma patients relapsing after high dose chemotherapy with autologous stem cell transplantation: data from the Japan Society for Haematopoietic Cell Transplantation registry. Br J Haematol, 186:e219-e223, 2019

50. Yamasaki S, Nitta H, Kondo E, Uchida N, Miyazaki T, Ishiyama K, Kiyota M, Matsuoka H, Ichinohe T, Fukuda T, Atsuta Y, Suzumiya J, Suzuki R. Effect of allogeneic hematopoietic cell transplantation for patients with T-prolymphocytic leukemia: a retrospective study from the Adult Lymphoma Working Group of the Japan Society for hematopoietic cell transplantation. Ann Hematol, 98:2213-2220, 2019

51. Hori D, Kobayashi R, Fujita N, Suzumiya J, Suzuki R, Kato K, Kawata T, Fukuda T, Inoue M, Goto H, Hama A, Iwato K, Okumura H, Eto T, Hashii Y, Atsuta Y, Mitsui T. The effectiveness of busulfan-based conditioning regimens for stem cell transplantation against lymphomas in children, adolescents, and young adults in Japan. Pediatr Blood Cancer, 66:e27918, 2019

52. Harada K, Tachibana T, Ohashi K, Ozawa Y, Sawa M, Kondo T, Ishikawa J, Onizuka M, Imada K, Fujisaki T, Tanaka J, Fukuda T, Atsuta Y, Kako S. The effect of melphalan dose and total body irradiation as reduced-intensity conditioning for acute lymphoblastic leukemia patients undergoing allogeneic stem cell transplantation. Leuk Lymphoma, 60:3521-3528, 2019

53. Kato H, Kato K, Kim SW, Fukuda T, Mori T, Sawa M, Ohno Y, Yoshioka S, Iwato Y, Taji H, Onizuka M, Kurahashi S, Ichinohe T, Suzumiya J, Suzuki R. Clinical outcomes of hepatitis B or C virus infections in patients with malignant lymphoma receiving autologous stem cell transplantation: on behalf of the Adult Lymphoma Working Group of the Japan Society for Haematopoietic Cell Transplantation (JSHCT). Br J Haematol, 186:e170-e175, 2019

54. Yanada M, Mori J, Aoki J, Masuko M, Harada K, Uchida N, Doki N, Fukuda T, Sakura T, Kanamori H, Sawa M, Kondo T, Katayama Y, Kanda J, Ichinohe T, Atsuta Y, Yano S. Allogeneic hematopoietic cell transplantation for patients with a history of multiple relapses of acute myeloid leukemia. Ann Hematol, 98:2179-2186, 2019

55. Harada K, Konuma T, Machida S, Mori J, Aoki J, Uchida N, Ohashi K, Fukuda T, Tanaka M, Ikegame K, Ozawa Y, Iwato K, Eto T, Onizuka M, Ichinohe T, Atsuta Y, Yano S. Risk Stratification and Prognosticators of Acute Myeloid Leukemia with Myelodysplasia-Related Changes in Patients Undergoing Allogeneic Stem Cell Transplantation: A Retrospective Study of the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant, 25:1730-1743, 2019

56. Mori T, Onishi Y, Ozawa Y, Kato C, Kai T, Kanda Y, Kurokawa M, Tanaka M, Ashida T, Sawayama Y, Fukuda T, Ichinohe T, Atsuta Y, Yamazaki H. Outcome of allogeneic hematopoietic stem cell transplantation in adult patients with hepatitis-associated aplastic anemia. Int J Hematol, 109:711-717, 2019

57. Shimomura Y, Hara M, Tachibana T, Ohashi K, Sakura T, Fukuda T, Nakazawa H, Iwato K, Kanda Y, Ikeda T, Eto T, Kanda J, Ichinohe T, Atsuta Y, Ishikawa T, Ishiyama K. Outcomes of second allogeneic haematopoietic stem cell transplantation in patients with relapse of myelodysplastic syndrome. Br J Haematol, 186:86-90, 2019

58. Fuji S, Miyamura K, Kanda Y, Fukuda T, Kobayashi T, Ozawa Y, Iwato K, Uchida N, Eto T, Ashida T, Mori T, Sawa M, Ichinohe T, Atsuta Y, Kanda J. Short-term clinical outcomes after HLA 1-locus mismatched uPBSCT are similar to that after HLA-matched uPBSCT and uBMT. Int J Hematol, 109:684-693, 2019

59. Kimura F, Kanda J, Ishiyama K, Yabe T, Yoshifuji K, Fukuda T, Ozawa Y, Iwato K, Eto T, Mori T, Uchida N, Ota S, Sakura T, Ichinohe T, Atsuta Y, Kanda Y. ABO blood type incompatibility lost the unfavorable impact on outcome in unrelated bone marrow transplantation. Bone Marrow Transplant, 54:1676-1685, 2019

60. Itonaga H, Ishiyama K, Aoki K, Aoki J, Ishikawa T, Uchida N, Ohashi K, Ueda Y, Fukuda T, Sakura T, Ohno Y, Iwato K, Okumura H, Kondo T, Ichinohe T, Takanashi M, Atsuta Y, Miyazaki Y. Increased opportunity for prolonged survival after allogeneic hematopoietic stem cell transplantation in patients aged 60-69 years with myelodysplastic syndrome. Ann Hematol, 98:1367-1381, 2019

61. Murata M, Takenaka K, Uchida N, Ozawa Y, Ohashi K, Kim SW, Ikegame K, Kanda Y, Kobayashi H, Ishikawa J, Ago H, Hirokawa M, Fukuda T, Atsuta Y, Kondo T. Comparison of Outcomes of Allogeneic Transplantation for Primary Myelofibrosis among Hematopoietic Stem Cell Source Groups. Biol Blood Marrow Transplant, 25:1536-1543, 2019

62. Sawayama Y, Itonaga H, Fukushima T, Nakano N, Fujiwara H, Utsunomiya A, Fukuda T, Miyamoto T, Eto T, Miyashita K, Nakamae H, Ogata M, Yamanoha A, Miyazaki Y, Kanda J, Atsuta Y, Kato K. Cytomegalovirus reactivation is associated with increased mortality more than 100 days after allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia/lymphoma. Am J Hematol, 94:E143-E146, 2019

63. Itonaga H, Ishiyama K, Aoki K, Aoki J, Ishikawa T, Ohashi K, Fukuda T, Ozawa Y, Ota S, Uchida N, Eto T, Iwato K, Ohno Y, Takanashi M, Ichinohe T, Atsuta Y, Miyazaki Y. Clinical impact of the loss of chromosome 7q on outcomes of patients with myelodysplastic syndromes treated with allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant, 54:1471-1481, 2019

64. Fujiwara SI, Kanda J, Tatara R, Ogawa H, Fukuda T, Okumura H, Ohashi K, Iwato K, Ueda Y, Ishiyama K, Eto T, Matsuoka KI, Nakamae H, Onizuka M, Atsuta Y, Kanda Y. Clinical significance of low-dose total body irradiation in HLA-mismatched reduced-intensity stem cell transplantation. Bone Marrow Transplant, 54:1327-1336, 2019

65. Kondo E, Ikeda T, Izutsu K, Chihara D, Shimizu-Koresawa R, Fujii N, Sakai T, Kondo T, Kubo K, Kato Y, Akasaka T, Fukuda T, Ichinohe T, Atsuta Y, Suzumiya J, Suzuki R. High-Dose Chemotherapy with Autologous Stem Cell Transplantation in Primary Central Nervous System Lymphoma: Data From the Japan Society for Hematopoietic Cell Transplantation Registry. Biol Blood Marrow Transplant, 25:899-905, 2019

66. Yamasaki S, Chihara D, Yoshida I, Kohda K, Sawa M, Ago H, Togitani K, Ohno Y, Tanaka J, Fukuda T, Atsuta Y, Suzumiya J, Suzuki R. Impact of hematopoietic stem cell transplantation in patients with relapsed or refractory marginal zone lymphoma. Ann Hematol, 98:1521-1523, 2019

67. Yoshimitsu M, Utsunomiya A, Fuji S, Fujiwara H, Fukuda T, Ogawa H, Takatsuka Y, Ishitsuka K, Yokota A, Okumura H, Ishii K, Nishikawa A, Eto T, Yonezawa A, Miyashita K, Tsukada J, Tanaka J, Atsuta Y, Kato K. A retrospective analysis of haplo-identical HLA-mismatch hematopoietic transplantation without posttransplantation cyclophosphamide for GVHD prophylaxis in patients with adult T-cell leukemia-lymphoma. Bone Marrow Transplant, 54:1266-1274, 2019

68. Maeda Y, Ugai T, Kondo E, Ikegame K, Murata M, Uchida N, Miyamoto T, Takahashi S, Ohashi K, Nakamae H, Fukuda T, Onizuka M, Eto T, Ota S, Hirokawa M, Ichinohe T, Atsuta Y, Kanda Y, Kanda J. HLA discrepancy between graft and host rather than that graft and first donor impact the second transplant outcome. Haematologica, 104:1055-1061, 2019

69. Yanada M, Masuko M, Mori J, Aoki J, Mizuno S, Fukuda T, Kakihana K, Ozawa Y, Ota S, Kanamori H, Mori T, Nakamae H, Eto T, Shiratori S, Maeda T, Iwato K, Ichinohe T, Kanda Y, Tanaka J, Atsuta Y, Yano S. Patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation: trends in survival during the past two decades. Bone Marrow Transplant, 54:578-586, 2019

70. Nakasone H, Tabuchi K, Uchida N, Ohno Y, Matsuhashi Y, Takahashi S, Onishi Y, Onizuka M, Kobayashi H, Fukuda T, Ichinohe T, Takanashi M, Kato K, Atsuta Y, Yabe H, Kanda Y. Which is more important for the selection of cord blood units for haematopoietic cell transplantation: the number of CD34-positive cells or total nucleated cells? Br J Haematol, 185:166-169, 2019

71. Fujimoto A, Hiramoto N, Yamasaki S, Inamoto Y, Uchida N, Maeda T, Mori T, Kanda Y, Kondo T, Shiratori S, Miyakoshi S, Ishiyama K, Ikegame K, Matsuhashi Y, Tanaka J, Ichinohe T, Atsuta Y, Ogata M, Suzuki R. Risk Factors and Predictive Scoring System For Post-Transplant Lymphoproliferative Disorder after Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant, 25:1441-1449, 2019